The “Fast Money” traders discuss which extreme stocks they would trade.
The "Fast Money" traders give you 8 ways to trade some extreme movers this week.
Jim Cramer says tech, bank, and drug stocks are getting a boost from the Trump administration.
CNBC's Dominic Chu reports on signals to watch before buying or selling stock using Bank of America, Gilead and the Powershares QQQ ETF as examples.
“Fast Money” Trader Guy Adami and Chad Morganlander, portfolio manager at Washington Crossing Advisors, talk about whether to buy, sell, or hold Starbucks, Amgen, Costco, Twilio, Gilead and Kroger.
Jim Cramer's not playing games when he relates main street’s hottest toy to the biggest stocks on Wall Street.
Jim Cramer rips through his take on caller favorite stocks, including semiconductor manufacturer Micron.
The high cost of health care in the US is nothing compared to the markup on some prescription medicines. We reveal the most expensive drugs.
Jim Cramer shares his take on caller favorite stocks, including this drugmaker.
One popular biotech-tracking ETF has gained 10 percent this year, and some strategists see more room to run.
Jim Cramer speeds through his take on caller favorite stocks, including this biopharmaceutical company.
The "Halftime Report" experts run through some of the day's biggest movers, including: Etsy, Gilead, Twilio, and Akamai.
These are the stocks posting the largest moves before the bell.
CNBC's Meg Tirrell reports on the Gilead conference call, after the company drops on earnings. The FM traders discuss.
CNBC's Meg Tirrell reports the latest from the Vertex Pharmaceuticals earnings call. The "Fast Money" traders weigh in on trading the pharma and biotech space.
Tax reform promises to spur corporate buying, but there are several reasons to not bet the house on stock buybacks.
Increases in the prices of drugs added $8.7 billion to 2016 net income for 28 companies analyzed, accounting for 100 percent of earnings growth last year.
Data covering the past five administrations show that Trump has enjoyed a relatively good, and surprising, market in his first 100 days.
Jim Cramer sped through his takes on caller favorite stocks, including Target, which is in a tough spot.
Asset prices are elevated everywhere, Oaktree Capital's Howard Marks says. Here's how he's investing.